Heidelberg Pharma AG
XETRA:HPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (150.7), the stock would be worth €-87.57 (3 250% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.8 | €2.78 |
0%
|
| Industry Average | 150.7 | €-87.57 |
-3 250%
|
| Country Average | 17.7 | €-10.28 |
-470%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Heidelberg Pharma AG
XETRA:HPHA
|
130.1m EUR | -4.8 | -3.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 23.4 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 27.5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.1 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 31.2 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 13.5 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 139.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 20.7 | 29.7 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 11.9 |
| Median | 17.7 |
| 70th Percentile | 29.2 |
| Max | 2 317.8 |
Other Multiples
Heidelberg Pharma AG
Glance View
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
